Japanese Government Procurement

National University Corporation - Notice of Procurement (Goods & Services)A Lenalidomide Hydrate (5㎎/1capsule 40capsules/1case) 220 cases,and 29 other contract

This procurement is covered by the WTO Agreement on Government Procurement, Japan-EU Economic Partnership Agreement or Japan-UK Comprehensive Economic Partnership Agreement.

Japanese

Publishing date Jan 16, 2024
Type of notice Notice of Procurement (Goods & Services)
Procurement entity National University Corporation - Osaka
Classification
0004 Medical & Pharmaceutical Products
Summay of notice ⑴ Official in charge of disbursement of the procuring entity : NISHIO Shojiro, President, Osaka University
⑵ Classification of the products to be procured : 4
⑶ Nature and quantity of the products to be purchased :
A Lenalidomide Hydrate (5㎎/1capsule 40capsules/1case) 220 cases
B Pembrolizumab (Genetical Recombination) (100㎎4㎖/1vial) 2,600 vials
C Bevacizumab (Genetical Recombination) (100㎎4㎖/1vial) 2,040 vials
D Bevacizumab (Genetical Recombination) (400㎎16㎖/1vial) 1,900 vials
E Ustekinumab (Genetical Recombination) (45㎎0.5㎖/1syringe) 740 syringes
F Infliximab (Genetical Recombination) (100㎎/1vial) 2,200 vials
G Pertuzumab (Genetical Recombination) (420㎎14㎖/1vial) 760 vials
H Eculizumab (Genetical Recombination) (300㎎30㎖/1vial) 140 vials
I Agalsidase Beta (Genetical Recombination) (35㎎/1vial) 260 vials
J Denosumab (Genetical Recombination) (120㎎1.7㎖/1vial) 1,840 vials
K Pegfilgrastim (Genetical Recombination) (3.6㎎0.36㎖/1syringe) 1,140 syringes
L Ipilimumab (Genetical Recombination) (50㎎10㎖/1vial) 200 vials
M Nusinersen Sodium (12㎎5㎖/1vial) 6 vials
N Atezolizumab (Genetical Recombination) (1200㎎20㎖/1vial) 220 vials
O Durvalumab (Genetical Recombination) (500㎎10㎖/1vial) 160 vials
P Nivolumab (Genetical Recombination) (240㎎24㎖/1vial) 1,340 vials
Q Elapegademase (2.4㎎1.5㎖/1vial) 100 vials
R Emicizumab (Genetical Recombination) (150㎎1.0㎖/1vial) 80 vials
S Tisagenlecleucel 12 bags
T Avelumab (Genetical Recombination) (200㎎10㎖/1vial) 460 vials
U Aflibercept (Genetical Recombination) (2㎎0.05㎖/1syringe) 5,140 syringes
V Satralizumab (Genetical Recombination) (120㎎1.0㎖/1syringe) 100 syringes
W Daratumumab (Genetical Recombination) (15㎖/1vial) 140 vials
X Lisocabtagene maraleucel 10 sets
Y Avalglucosidase Alfa (Genetical Recombination) (100㎎/1vial) 340 vials
Z Ravulizumab (Genetical Recombination) (300㎎3㎖/1vial) 1,040 vials
AA Faricimab (Genetical Recombination) (28.8㎎0.24㎖/1vial) 500 vials
AB Idecabtagene vicleucel 1 bag
AC Vutrisiran Sodium (25㎎0.5㎖/1syringe) 18 syringes
AD Axicabtagene ciloleucel (1 bag) 1 bag
⑷ Delivery period : By 1 April, 2024 through 31 March, 2025
⑸ Delivery place : Osaka University Hospital and Dental Hospital
⑹ Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall :
A not come under Article 7 and 8 of the Regulation concerning the Contract for Osaka University,
B have the Grade A or Grade B qualification during fiscal 2024 in the Kinki area in sales of product for participating in tenders by Single qualification for every ministry and agency, or in tenders by Osaka University,
C prove to have obtained either the first-class license or the third-class license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices.
D prove to have the ability to deliver the products, required by this notice, on the date and to the place specified by President.
⑺ Time limit of tender : 12 : 00 8 March, 2024
⑻ Contact point for the notice : MATSUO Takenori, Procurement Section, Accounting Division, Osaka University Hospital, 2-15 Yamadaoka Suita shi Osaka 565-0871 Japan, TEL 06-6879-5116
⑼ Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.